One Peptide, Three Supply Chains: What Does Your COA Actually Prove?

Adapted from AVL Laboratory’s analysis of peptide supply-chain transparency

In early 2026, an independent lab team purchased 10 common research peptides from four different tiers of suppliers. The samples were sent to a third-party laboratory for purity, identity, endotoxin, and heavy-metal testing.

Three of the 10 samples failed. One product labeled “semaglutide” was not semaglutide at all. It was the wrong compound.

That result was troubling, but not surprising. The more revealing part came afterward, when researchers traced the supply chain upward. They found that the same peptide—sometimes even the same batch—was appearing on multiple supplier websites that looked completely unrelated.

One peptide. One batch number. Three different supply-chain stories.

The Three “Nationalities” of a Peptide Chain

Global peptide active pharmaceutical ingredient (API) production is highly concentrated. According to a 2023 analysis in International Pharmaceutical Manufacturing, China produces roughly 68% of the world’s peptide APIs.

But that 68% does not move through a single pipeline. It reaches end users through three very different routes.

1. Direct From Chinese Factories to Consumers

This is the shortest path—and usually the cheapest.

Many Chinese peptide manufacturers and traders sell directly to overseas customers through platforms such as Alibaba, or through research-market suppliers such as Nexaph and EZ Peptides.

The defining feature of this route is how the COA is obtained. The supplier pays to have the COA listed on the same product page. The customer receives the product and can compare the lot number and batch number against the certificate.

The problem: these COAs are often issued internally by the manufacturer, not by a genuinely independent third-party laboratory.

2. U.S. White-Labeling and Repackaging

Large quantities of Chinese-made peptide raw powder arrive in the United States, where they are aliquoted, relabeled, and sold under an American brand.

On the surface, the product appears to come from a U.S. company. The COA lists a U.S. address. Everything fits the psychological expectation of “local sourcing.”

But the true origin of the raw material is often erased during repackaging. Industry surveys suggest that a significant share of U.S. suppliers are not actual manufacturers. They are repackagers.

3. Europe’s Compliance Premium and Long Lead Times

Europe has some of the world’s most mature peptide synthesis facilities, with Switzerland and Denmark concentrating the most advanced manufacturers.

The European market is projected to reach roughly $9.8 billion in 2026, growing at 8.9%—below the global average, largely because of strict regulatory approval cycles.

The trade-off is clear:

• Highest price

• Longest waiting time

• But also a traceable regulatory chain and genuine third-party testing

The Truth Behind Shared COAs

In April 2026, a post in the peptide research community sparked widespread discussion. A user discovered that a single-vial peptide product purchased from EZ Peptides had a COA identical to one from Nexaph.

Community members clarified the relationship: EZ sources single-vial products from Nexaph. The two companies are sister companies. Nexaph functions more like the parent, while EZ handles retail.

Same source. Same COA.

This is not an isolated case. Finnrick’s supplier intelligence report found more direct evidence: a tirzepatide batch identifier from P3 Labz also appeared on a product from the Uther brand. The report described this as shared upstream wholesale supply, not original manufacturing by P3 Labz.

An even more extreme example came from a New York Times article and the discussion around it. One industry insider put it bluntly:

“Today, 90% of peptides have some part made somewhere in China—maybe Hong Kong—and then either bottled whole or shipped as raw material to facilities in the U.S. or elsewhere for bottling.”

He added a critical detail:

“If the raw material traces back to the same manufacturer, many COAs are shared.”

What does this mean?

A COA proves that “this batch passed a certain test.” It does not prove that “this product came from the supplier you think it did.”

When multiple brands share the same raw material from the same peptide chain, they can legally cite the same COA. What the consumer sees as an “independent lab report” may, at the supply-chain level, be the same document photocopied multiple times.

The Authenticity Problem in Third-Party Testing

Janoshik Analytical is one of the most frequently cited third-party testing labs in the peptide research community.

A genuine Janoshik report is difficult to fake. It includes a test ID, a QR code, and can be verified through the official portal. The batch number must match the bottle actually received.

In 2024, 43% of peptides tested by Janoshik failed to meet their labeled purity. That number alone shows that even a real, verifiable third-party COA does not guarantee a compliant product.

The deeper problem is that not every COA marketed as “third-party tested” comes from a truly independent laboratory.

A 2026 industry analysis stated clearly that overseas COAs—especially those from Chinese manufacturers—have no regulatory force in the United States and are often issued internally by the manufacturer rather than by a genuinely independent third party.

There is also a more subtle issue: the “lifecycle” of a batch.

One supplier explained in a community discussion that if multiple strengths—different milligram amounts—come from the same production batch, they share a base batch ID. That is normal.

But if the batch corresponding to a COA has sold out and a new batch has not yet been tested, some suppliers will continue displaying the old COA because “the purity is probably about the same.”

Procurement Logic Across the Three Paths

When facing three supply-chain paths, the core question is not “Which one is best?”

The real question is: Which path’s risks match my needs?

Direct From China

Reasonable when:

• You have independent verification capability.

• Or you are willing to absorb the cost of verification.

What to do:

• Obtain the COA.

• Verify the test ID through Janoshik or a similar official portal.

• Match the batch number against the physical product.

• If the COA cannot be verified, treat it as marketing material, not a quality document.

U.S. White-Label Suppliers

Reasonable when:

• You need faster delivery and local after-sales support.

• You accept one fact: a U.S. address does not equal U.S. manufacturing.

What to do:

• Before bulk purchasing, ask for the raw material COA, not just the finished-product COA.

• Confirm whether the raw material source is traceable.

European Compliant Suppliers

Reasonable when:

• Your application has hard regulatory compliance requirements.

• Or your research project cannot tolerate the cost of quality failure.

What you are buying:

• Traceability

• Regulatory backing

• Not simply “a better peptide”

Conclusion

One peptide. Three supply chains. Three COA stories.

When the industry’s core quality document—the COA—can be shared, reused, or repackaged across different brands, the procurement question must change.

It is no longer enough to ask:

“Is there a COA?”

The better question is:

“Which batch, which laboratory, and which supply chain does this COA actually correspond to?”

One insider’s comment deserves to be read slowly:

“The closer you buy to the Chinese manufacturer, the more reliable the COA the supplier pays to put on the page next to the peptide.”

The implicit premise is this: you already know what you are buying, where it comes from, and what needs to be verified.

For participants in the research peptide market, supply-chain transparency is becoming scarcer than purity percentage.

Purity can be expressed as a number.

Transparency can only be tested with questions:

• Who made this batch?

• Who issued the COA?

• Can I independently verify it?